National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: Updated NCCN Guidelines, NCCN Compendium, & NCCN Guidelines with NCCN Evidence Blocks™

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Ovarian Cancer. These NCCN Guidelines® are currently available as Version 5.2017.

  • Monitoring/follow-up for stage I-IV disease following complete response to primary therapy (OV-5)
    • Tumor molecular testing has been added to the follow-up recommendations if rising CA-125 and/or clinical relapse occurs during monitoring/follow-up for recurrent disease.
    • Footnote “w” has been added: “Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Testing should include at least: BRCA 1/2, homologous recombination pathway genes, and microsatellite instability or DNA mismatch repair.” (Also on OV-6)
  • Acceptable Recurrence Therapies for Epithelial (including LCOH)/Fallopian Tube/Primary Peritoneal Cancer Options OV-B (6 of 8)
    • The following targeted therapy has been added to the list of other potentially active recurrence therapy options: Pembrolizumab (category 2A) (for microsatellite instability-high [MSI-H] or mismatch repair deficient [dMMR] solid tumors) (Varga A, Piha-Paul SA,  Ott PA, et al. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028 [abstract]. J Clin Oncol 2017;35: Abstract 5513.)


*For your reference, the previous update (Version 4.2017) to the NCCN Guidelines for Ovarian Cancer, published on November 9, 2017 is available at the following link:


NCCN has published updates to the following NCCN Guidelines with NCCN Evidence Blocks™:

  • Bladder Cancer, Version 1.2018
  • Penile Cancer, Version 1.2018


For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps for iPhone, iPad, and Android smartphones & tablets are now available! Visit

About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

Please note: The NCCN Third Party Content FTP site: has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2018 National Comprehensive Cancer Network. All Rights Reserved.